Oliver C. Cohen

931 total citations
8 papers, 96 citations indexed

About

Oliver C. Cohen is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Oliver C. Cohen has authored 8 papers receiving a total of 96 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Hematology and 2 papers in Genetics. Recurrent topics in Oliver C. Cohen's work include Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Immunotherapy and Immune Responses (2 papers). Oliver C. Cohen is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Immunotherapy and Immune Responses (2 papers). Oliver C. Cohen collaborates with scholars based in United Kingdom and Denmark. Oliver C. Cohen's co-authors include Ashutosh Wechalekar, Kwee Yong, Andrew J.S. Furness, Dominic Patel, Manuel Rodriguez‐Justo, Lucía Conde, Sergio A. Quezada, Lydia Lee, Ehsan Ghorani and Javier Herrero and has published in prestigious journals such as Blood, Clinical Cancer Research and British Journal of Haematology.

In The Last Decade

Oliver C. Cohen

5 papers receiving 95 citations

Peers

Countries citing papers authored by Oliver C. Cohen

Since Specialization

Citations

This map shows the geographic impact of Oliver C. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver C. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver C. Cohen more than expected).

Fields of papers citing papers by Oliver C. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver C. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver C. Cohen. The network helps show where Oliver C. Cohen may publish in the future.

Co-authorship network of co-authors of Oliver C. Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver C. Cohen. A scholar is included among the top collaborators of Oliver C. Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver C. Cohen. Oliver C. Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis 2025 ·British Journal of Haematology ·Jahanzaib Khwaja, Sriram Ravichandran, Oliver C. Cohen, Darren Foard, (unknown), Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Carol Whelan, Shameem Mahmood, Ashutosh Wechalekar	1
2	Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System 2024 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, (unknown), Oliver C. Cohen, Darren Foard, Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, Amy A. Kirkwood, Ashutosh Wechalekar	0
3	Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma 2020 ·Clinical Cancer Research ·Nouf M. Al‐Rasheed, Lydia Lee, Ehsan Ghorani, Jake Y. Henry, Lucía Conde, (unknown), (unknown), Andrew J.S. Furness, Selina J Chavda, (unknown), (unknown), Oliver C. Cohen, Dominic Patel, Anthony G. Brooks, Manuel Rodriguez‐Justo, Martin Pulé, Javier Herrero, Sergio A. Quezada, Kwee Yong	50
4	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis 2020 ·British Journal of Haematology ·Oliver C. Cohen, Faye Sharpley, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Marianna Fontana, Carol Whelan, Ana Martinez–Naharro, Charalampia Kyriakou, Neil Rabin, Rakesh Popat, Kwee Yong, (unknown), (unknown), Philip N. Hawkins, Ashutosh Wechalekar	28
5	Systemic amyloidosis: moving into the spotlight 2020 ·Leukemia ·Oliver C. Cohen, Ashutosh Wechalekar	14
6	Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Oliver C. Cohen, Faye Sharpley, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Cristina Quarta, Marianna Fontana, Carol Whelan, Ana Martinez–Naharro, Charalampia Kyriakou, Neil Rabin, Rakesh Popat, Kwee Yong, (unknown), (unknown), Philip N. Hawkins, Ashutosh Wechalekar	0
7	Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome 2019 ·Blood ·Nouf M. Al‐Rasheed, Lydia Lee, (unknown), William Wilson, Oliver C. Cohen, Selina J Chavda, Jake Y. Henry, Andrew J.S. Furness, (unknown), (unknown), Charalampia Kyriakou, Neil Rabin, Sergio A. Quezada, Kwee Yong	0
8	Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study 2016 ·Blood ·Oliver C. Cohen, Neil Rabin, Nicholas Counsell, Roger G. Owen, Bilyana Popova, (unknown), (unknown), Andy C. Rawstron, (unknown), Ruth M. de Tute, Derralynn Hughes, Sally Moore, Paul Smith, Kwee Yong	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact